Emerging evidence suggests that glucose-lowering therapies may influence long-term brain health. A study published in Cardiovascular Diabetology evaluated whether GLP-1 receptor agonists reduce the risk of neurodegenerative disorders in people with type 2 diabetes.

Using the TriNetX global health network, the analysis included 214,442 individuals initiating either GLP-1 RAs or DPP4i between 2010 and 2021. Participants had no prior neurodegenerative disease and were followed for up to five years. During a mean follow-up of four years, new neurodegenerative conditions developed in 2.2% of those starting GLP-1 receptor agonists versus 2.9% starting DPP4 inhibitors (hazard ratio 0.81, 95% CI 0.77–0.86). 

Reductions were seen for dementia (HR 0.76), Alzheimer’s disease (HR 0.77), and vascular dementia (HR 0.75). Results were consistent among women and men, people older than 65 years and younger than 65 years, and across semaglutide, liraglutide, and dulaglutide. Similar directional findings were observed when comparing GLP-1 receptor agonists with basal insulin.

These findings indicate that GLP-1 receptor agonist therapy may help lower the risk of neurodegenerative disease in type 2 diabetes. Because of the observational design and lack of adherence data, prospective trials are needed to confirm whether GLP-1–based therapies offer neuroprotective benefit.